$COLL - On our trading list. Overweight rating with a $27 price target by Piper today.Piper reiterates Overweight on Collegium after physician surveyPiper Sandler analyst David Amsellem reiterates an Overweight rating on Collegium Pharmaceutical with a $27 price target after conducting a survey of 49 physicians who have significant experience prescribing schedule II extended-release opioids for chronic pain, and specifically are frequent prescribers of OxyContin. A significant majority of respondents perceive a lower risk of abuse/misuse for Collegium's Xtampza ER relative to that of OxyContin, and significant majorities plan to prescribe Xtampza ER more frequently over the next two years, Amsellem tells investors in a research note. The analyst continues to expect that Xtampza will emerge as the most widely prescribed schedule II extended-release opioid product, with peak sales solidly in the $300M-$400M range. $COLL, Collegium Pharmaceutical, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page